Browsing by Author "Alvares-da-Silva, Mario Reis"

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Assessing the impact of COVID-19 on liver cancer management (CERO-19)
    (2021) Munoz-Martinez, Sergio; Sapena, Victor; Forner, Alejandro; Nault, Jean-Charles; Sapisochin, Gonzalo; Rimassa, Lorenza; Sangro, Bruno; Bruix, Jordi; Sanduzzi-Zamparelli, Marco; Holowko, Waclaw; El Kassas, Mohamed; Mocan, Tudor; Bouattour, Mohamed; Merle, Philippe; Hoogwater, Frederik J. H.; Alqahtani, Saleh A.; Reeves, Helen L.; Pinato, David J.; Giorgakis, Emmanouil; Meyer, Tim; Villadsen, Gerda Elisabeth; Wege, Henning; Salati, Massimiliano; Minguez, Beatriz; Di Costanzo, Giovan Giuseppe; Roderburg, Christoph; Tacke, Frank; Varela, Maria; Galle, Peter R.; Alvares-da-Silva, Mario Reis; Trojan, Joerg; Bridgewater, John; Cabibbo, Giuseppe; Toso, Christian; Lachenmayer, Anja; Casadei-Gardini, Andrea; Toyoda, Hidenori; Luedde, Tom; Villani, Rosanna; Matilla Pena, Ana Maria; Guedes Leal, Cassia Regina; Ronzoni, Monica; Delgado, Manuel; Perello, Christie; Pascual, Sonia; Luis Lledo, Jose; Argemi, Josepmaria; Basu, Bristi; da Fonseca, Leonardo; Acevedo, Juan; Siebenhuener, Alexander R.; Braconi, Chiara; Meyers, Brandon M.; Granito, Alessandro; Sala, Margarita; Rodriguez-Lope, Carlos; Blaise, Lorraine; Romero-Gomez, Manuel; Pinero, Federico; Gomez, Dhanny; Mello, Vivianne; Pinheiro Alves, Rogerio Camargo; Franca, Alex; Branco, Fernanda; Brandi, Giovanni; Pereira, Gustavo; Coll, Susanna; Guarino, Maria; Benitez, Carlos; Margarita Anders, Maria; Bandi, Juan C.; Vergara, Mercedes; Calvo, Mariona; Peck-Radosavljevic, Markus; Garcia-Juarez, Ignacio; Cardinale, Vincenzo; Lozano, Mar; Gambato, Martina; Okolicsanyi, Stefano; Morales-Arraez, Dalia; Elvevi, Alessandra; Munoz, Alberto E.; Lue, Alberto; Iavarone, Massimo; Reig, Maria
    Background & Aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.
  • No Thumbnail Available
    Item
    Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population
    (2020) Zambrano-Huailla, Rommel; Guedes, Laura; Stefano, Jose Tadeu; de Souza, Arthur A. Arrais; Marciano, Sebastian; Yvamoto, Erika; Michalczuk, Matheus Truccolo; Vanni, Denise Siqueira; Rodriguez, Hernan; Carrilho, Flair Jose; Alvares-da-Silva, Mario Reis; Gadano, Adrian; Arrese, Marco; Miranda, Adelina Lozano; Oliveira, Claudia P.
    Introduction and aims: Several non-invasive scoring systems have been developed and validated worldwide to predict the risk of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). However, information about the performance of these systems in Latin American populations is scarce. Our aim was to evaluate the performance of the Hepamet Fibrosis Score, Fibrosis-4 (FIB-4) and the NAFLD Fibrosis Score (NFS) in a mixed Latin American group of NAFLD patients.
  • No Thumbnail Available
    Item
    Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
    (2024) Kowdley, Kris V.; Bowlus, Christopher L.; Levy, Cynthia; Akarca, Ulus S.; Alvares-da-Silva, Mario Reis; Andreone, Pietro; Arrese, Marco; Corpechot, Christophe; Francque, Sven M.; Heneghan, Michael A.; Invernizzi, Pietro; Jones, David; Kruger, Frederik C.; Lawitz, Eric; Mayo, Marlyn J.; Shiffman, Mitchell L.; Swain, Mark G.; Valera, Jose Miguel; Vargas, Victor; Vierling, John M.; Villamil, Alejandra; Addy, Carol; Dietrich, Julie; Germain, Jean-Michel; Mazain, Sarah; Rafailovic, Dragutin; Tadde, Bachirou; Miller, Benjamin; Shu, Jianfen; Zein, Claudia O.; Schattenberg, Jorn M.
    Background Primary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis. Whether elafibranor, an oral, dual peroxisome proliferator-activated receptor (PPAR) alpha and delta agonist, may have benefit as a treatment for primary biliary cholangitis is unknown.
  • No Thumbnail Available
    Item
    Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease
    (2020) Pablo Arab, Juan; Dirchwolf, Melisa; Alvares-da-Silva, Mario Reis; Barrera, Francisco; Benitez, Carlos; Castellanos-Fernandez, Marlene; Castro-Narro, Graciela; Chavez-Tapia, Norberto; Chiodi, Daniela; Cotrim, Helma; Cusi, Kenneth; Marques Souza de Oliveira, Claudia Pinto; Diaz, Javier; Fassio, Eduardo; Gerona, Solange; Girala, Marcos; Hernandez, Nelia; Marciano, Sebastian; Masson, Walter; Mendez-Sanchez, Nahum; Leite, Nathalie; Lozano, Adelina; Padilla, Martin; Panduro, Arturo; Parana, Raymundo; Parise, Edison; Perez, Marlene; Poniachik, Jaime; Carlos Restrepo, Juan; Ruf, Andres; Silva, Marcelo; Tagle, Martin; Tapias, Monica; Torres, Kenia; Vilar-Gomez, Eduardo; Costa Gil, Jose Eduardo; Gadano, Adrian; Arrese, Marco
    Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20-30% of the general population. Furthermore, its prevalence is predicted to increase exponentially in the next decades, concomitantly with the global epidemic of obesity, type 2 diabetes mellitus (T2DM), and sedentary lifestyle. NAFLD is a clinical syndrome that encompasses a wide spectrum of associated diseases and hepatic complications such as hepatocellular carcinoma (HCC). Moreover, this disease is believed to become the main indication for liver transplantation in the near future. Since NAFLD management represents a growing challenge for primary care physicians, the Asociacion Latinoamericana para el Estudio del Higado (ALEH) has decided to organize this Practice Guidance for the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease, written by Latin-American specialists in different clinical areas, and destined to general practitioners, internal medicine specialists, endocrinologists, diabetologists, gastroenterologists, and hepatologists. The main purpose of this document is to improve patient care and awareness of NAFLD. The information provided in this guidance may also be useful in assisting stakeholders in the decision-making process related to NAFLD. Since new evidence is constantly emerging on different aspects of the disease, updates to this guideline will be required in future. (C) 2020 Published by Elsevier Espana, S.L.U. on behalf of Fundacion Cilnica Medica Sur, A.C.
  • Thumbnail Image
    Item
    The effects of elafibranor in people with primary biliary cholangitis: a plain language summary
    (Taylor and Francis Ltd., 2025) Kowdley, Kris V.; Bowlus, Christopher; Levy, Cynthia; Akarca, Ulus S.; Alvares-da-Silva, Mario Reis; Andreone, Pietro; Arrese, Marco; Francque, Sven M.; Heneghan, Michael A.; Invernizzi, Pietro; Jones, David; Lawitz, Eric; Mayo, Marlyn J.; Swain, Mark G.; Vargas, Victor; Vierling, John M.; Villamil, Alejandra; Addy, Carol; Dietrich, Julie; Mazain, Sarah; Taddé, Bachirou; Miller, Benjamin; Shu, Jianfen; Zein, Claudia O.; Roberts, Carol; Wright, Gail; Schattenberg, Jörn M.
    This is a plain language summary describing the phase 3 clinical trialcalled ‘ELATIVE®’. Primary biliary cholangitis (PBC) is a rare disease of the liverthat can get worse over time and can be potentially life threatening. Livingwith PBC can also reduce a person’s quality of life. There are currently notmany treatment options available for PBC. The ELATIVE® clinical trial testedhow well a potential new treatment called ‘elafibranor’ works in treatingpeople with PBC.